 LONDON, Aug. 25, 2021 GLOBE NEWSWIRE -- Achilles Therapeutics plc NASDAQ: ACHL, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that US patent US 11,098,121 and European patent EP3347039B have been granted. The patents cover a method of identifying cancer patients that are likely to respond to a checkpoint inhibitor CPI by determining the total number of clonal neoantigens or the ratio of clonal to subclonal neoantigens in patients cancer cells. Clonal neoantigens are neoantigens present on all tumor cells and absent from healthy tissue. 